SOHO 4th Italian Conference

www.sohoitaly.com

 

SOHO 4th Italian Conference
Avatar

SOHO Italy 2022: Phase 3 AGILE Study - A Global, Randomized, Double-Blind Study of Ivo + Aza vs. Placebo + Aza in Newly Diagnosed AML With an IDH1 Mutation

By SOHO 4th Italian Conference FEATURING Claudio Cerchione
By SOHO 4th Italian Conference FEATURING Claudio Cerchione
0 views
November 28, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon
Leukemia
07:55
SOHO 4th Italian Conference

SOHO Italy 2022: Targeting Novel Oncogenic Dependencies in AML With …

Feat. S. Peruzzi
09:58
SOHO 4th Italian Conference

SOHO Italy 2022: Role of BCOR and DNMT3A Cooperation in the Epigenet…

Feat. A. Scialdone
15:16
SOHO 4th Italian Conference

SOHO Italy 2022: How I Treat Blastic Plasmacytoid Dendritic Cell Neo…

Feat. N. Pemmaraju
17:22
SOHO 4th Italian Conference

SOHO Italy 2022: Mutation Profiling of AML Patients

Feat. N. Daver
12:25
SOHO 4th Italian Conference

SOHO Italy 2022: How I Treat Lymphoblastic Leukemia

Feat. G. Martinelli
14:30
Elias Jabbour

How I Treat the Older Adult With ALL

12:48
SOHO 4th Italian Conference

SOHO Italy 2022: Approach to pH+ and pH-Like ALL

Feat. C. Papayannidis
16:32
SOHO 4th Italian Conference

SOHO Italy 2022: How I Treat CML at MDACC in 2022

Feat. E. Jabbour
15:17
SOHO 4th Italian Conference

SOHO Italy 2022: How I Treat CLL at MDACC

Feat. A. Ferrajoli
16:34
SOHO 4th Italian Conference

SOHO Italy 2022: The History of CML - From Nightmare to the Cure

Feat. G. Saglio
15:59
SOHO 4th Italian Conference

Non-Intensive Treatment of Older/Unfit Patients With AML

Feat. T. Kadia
11:33
SOHO 4th Italian Conference

SOHO Italy 2022: Mutations in AML and the Importance of Molecular Te…

Feat. G. Martinelli
18:58
SOHO 4th Italian Conference

SOHO Italy 2022: FLT3 Mutations in AML

Feat. N. Daver
08:12
SOHO 4th Italian Conference

SOHO Italy 2022: Why We Should Not Forget Glasdegib in AML

Feat. A. de la Fuente
08:05
SOHO 4th Italian Conference

SOHO Italy 2022: Phase 3 AGILE Study - A Global, Randomized, Double-…

Feat. C. Cerchione
16:47
SOHO 4th Italian Conference

SOHO Italy 2022: Immune Antibodies and Cellular Therapies in AML

Feat. N. Daver
14:16
SOHO 4th Italian Conference

SOHO Italy 2022: Secondary AML - What’s New

Feat. A. Isidori
10:25
SOHO 4th Italian Conference

SOHO Italy 2022: Pivekimab Sunirine Triplet With Aza & Ven Shows…

Feat. N. Daver
16:47
SOHO 4th Italian Conference

SOHO Italy 2022: New Insights Into AML Biology and Their Concrete an…

Feat. I. Iacobucci
15:43
SOHO 4th Italian Conference

SOHO Italy 2022: Pro-Apoptotic Pathways in AML

Feat. S. Galimberti
13:17
SOHO 4th Italian Conference

SOHO Italy 2022: New Frontiers in Overcoming Environment-Mediated Dr…

Feat. C. Cerchione
20:11
SOHO 4th Italian Conference

SOHO Italy 2022: Present and Future Perspective for Cellular Therapy…

Feat. A. Rambaldi
14:06
SOHO 4th Italian Conference

Maintenance in AML: Trials or Reality?

Feat. M. Gottardi
20:27
SOHO 4th Italian Conference

SOHO Italy 2022: Next Questions in ALL

Feat. G. Martinelli
26:45
SOHO 4th Italian Conference

SOHO Italy 2022: State-of-the-Art and Next Questions in CML Therapy

Feat. G. Saglio